Extending the Potential of the Treatment of Multiple Sclerosis with a New Agent for Oral Use – Teriflunomide (Aubagio) | springermedicine.com

Springer Medicine

Top

Neuroscience and Behavioral Physiology

Published in:

01-01-2017

Extending the Potential of the Treatment of Multiple Sclerosis with a New Agent for Oral Use – Teriflunomide (Aubagio)

Authors: N. V. Khachanova, T. V. Gorokhova

Published in: Neuroscience and Behavioral Physiology | Issue 1/2017

Login to get access

Title: Extending the Potential of the Treatment of Multiple Sclerosis with a New Agent for Oral Use – Teriflunomide (Aubagio)
Authors: N. V. Khachanova
T. V. Gorokhova
Publication date: 01-01-2017
Publisher: Springer US
Published in: Neuroscience and Behavioral Physiology / Issue 1/2017
Print ISSN: 0097-0549
Electronic ISSN: 1573-899X
DOI: https://doi.org/10.1007/s11055-016-0372-0

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties